

# Fig. 1




A = Eprex
B = PER.C6-α2,6ST-EPO
C = PER.C6-EPO

# Fig. 2


A.




# Fig. 2

## PER.C6-EPO-022 (Suspension, VPRO)

B.



# Fig. 3





1 = PER.C6-EPO in VPRO
2 = PER.C6-EPO + α2,6 ST in VPRO
3 = EPREX

**Fig. 4**

PER.C6-EPO


**A.**




* Number of sialic acids per glycan


PER.C6-ST-EPO

**B.**





* Number of sialic acids per glycan


# Fig. 5


1 2
3 4
Fractionation using chromatography
12
11
10
9
8
8
7
6
5
4
3
2
1
sialic acid content
1 = PER.C6-EPO
2 = PER.C6-ST-EPO
3 = Fractionated PER.C6-ST-EPO
4 = Eprex®

# Fig. 6




# Fig. 7



avg. sialic acid content:
3.0
9.0
12.6
12.4
1
2
3
4
EPO isoforms
(number of sialic acids per EPO molecule)
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0

# Fig. 8


A.


Amp
CMV
ColE1
BGH p(A)
pCP-EPO
7334 bp
f1 ori
BGH p(A)
SV40
EPO
Neo
CMV
SV40 p(A)


B.


Amp
CMV
ColE1
ST3 GALIV
pEPO-ST3
8306 bp
BGH p(A)
BGH p(A)
EPO
f1 ori
SV40
CMV
SV40 p(A)
Neo


# Fig. 9



# Fig. 10



# Fig. 11


2541.44
4514.7
100
90
80
70
60
50
40
30
20
10
0
% Intensity
2176.27
2544.31
2582.45
2184.30
0
1200
1660
2120
2580
3040
3500
Mass (m/z)

# Fig. 12

